Ryan McDonald

Ryan McDonald, Associate Editorial Director for CURE®, has been with the team since February 2020 and has previously covered medical news across several specialties prior to joining MJH Life Sciences. He is a graduate of Temple University, where he studied journalism and minored in political science and history. He considers himself a craft beer snob and would like to open a brewery in the future. During his spare time, he can be found rooting for all major Philadelphia sports teams. Follow Ryan on Twitter @RMcDonald11 or email him at rmcdonald@curetoday.com.

Educated Patient® Metastatic Breast Cancer Summit Clinical Trials Presentation: June 11, 2022

June 30, 2022

Video

Watch Dr. Kevin Kalinsky, from Winship Cancer Institute of Emory University, discuss joining clinical trials, during the CURE Educated Patient Metastatic Breast Cancer Summit.

FDA to Speed Up Review of Novel Drug for Mesothelioma Not Treatable by Surgery

June 28, 2022

Article

The FDA plans to accelerate its review of IK-930, an investigational drug, for the treatment of patients with unresectable NF2-deficient malignant pleural mesothelioma, a rare cancer.

FDA Grants Orphan Drug Designation to Novel CAR-T Cell Therapy to Treat Waldenstrom Macroglobulinemia, a Rare Type of Cancer

June 27, 2022

Article

Treatment with the novel CAR-T cell therapy was associated with favorable efficacy and safety results in a group of patients with follicular lymphoma, including a few with Waldenstrom macroglobulinemia, according to findings from a study presented at a recent medical conference.

Educated Patient® Metastatic Breast Cancer Summit Metastatic Triple-Negative Presentation: June 11, 2022

June 26, 2022

Video

Watch Dr. Keerthi Gogineni, from Emory University School of Medicine, discuss the management of triple-negative disease, during the CURE Educated Patient Metastatic Breast Cancer Summit.